Overview

Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Single-centre, open-label, randomised, two-way crossover study in 28 healthy volunteers. The study consisted of two consecutive single-dose treatment periods separated by a washout period of 14 days or more.
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Opicapone